Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 10/20 | 0.34 |
| ▸ | CNR1 | P21554 | 10/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308257 | 0.93 | L3MBTL1 (0.34) | OPRM1P2RX7L3MBTL1CNR2 | |
| SCHEMBL3299195 | 0.93 | L3MBTL1 (0.34) | OPRM1P2RX7L3MBTL1 | |
| SCHEMBL1818958 | 0.86 | SCN9A (0.37) | L3MBTL1 | |
| SCHEMBL3306666 | 0.83 | OPRM1 (0.36) | OPRM1P2RX7 | |
| SCHEMBL1815542 | 0.82 | HDAC9 (0.33) | L3MBTL1 | |
| SCHEMBL1816105 | 0.82 | KDM4E (0.44) | OPRM1L3MBTL1CNR2CNR1GAA | |
| SCHEMBL3261317 | 0.81 | NTRK1 (0.38) | P2RX7 | |
| SCHEMBL1814343 | 0.81 | NR1H4 (0.33) | P2RX7L3MBTL1 | |
| SCHEMBL1819945 | 0.80 | ADORA1 (0.48) | OPRM1P2RX7 | |
| SCHEMBL3303524 | 0.75 | ADORA1 (0.51) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321296-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | OPRM1 3853/4885P2RX7 473/4885L3MBTL1 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.